Eris Lifesciences (HOLD): Strong quarter; cut to HOLD post recent rally
Q1 EBITDA/PAT growth strong at 22%/20% YoY to Rs 1.3bn/Rs 1.1bn, meeting street estimates
339 Views
EM Pullback Opportunity
Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...
543 Views
Eris Lifesciences - 2QFY19 – Acquisitions Drive Top Line Much Higher, Bottom Line to Follow by FY20E
Eris Lifesciences (ERIS IN) reported lower than expected performance in 2QFY19. Revenues were 5% lower than our estimates at Rs 2,642 mn. The...
503 Views
ERIS Lifesciences – FY18 Annual Report Analysis - Strong Rebound in Cash Flow Likely from FY19E
We reviewed the FY18 Annual Report of Eris Lifesciences (ERIS IN). Eris reported the negative free cash flow of ~Rs 3,148 mn due to business...
526 Views
Eris Lifesciences - 1QFY19 – Strides Assimilation on Track
Eris Lifesciences (ERIS IN) reported revenue growth of 35% YoY to Rs 2.5 bn (+18% QoQ), EBITDA growth of 24% YoY to Rs 886 mn (+23% QoQ) and...
333 Views